Demand For All Inclusive Prostate Cancer Care Treatment Centers In High Demand Among Urologists Who Diagnose Prostate Cancers Oncology Med Unveils Investor (Urology) Owned Turnkey Cancer Center Model

Share Article

Oncology Med, Inc. (Pink Sheets "ONCO") Oncology Med, a Pittsburgh based cancer treatment solutions group, today unveiled its full turnkey cancer center investor model for urology investor physicians, as well as, other interested parties.

The model is designed to establish 'centers of excellence' and to be a win-win for the patients, physicians, and payers while providing a total continuity of care for each patient.

Oncology Med, Inc. (OMI) has developed a full turnkey cancer treatment center model to meet the ever changing healthcare market and allows for surgeons to be more directly involved in a full turnkey cancer treatment model for their patients. The model also meets the demand for more cost effective curative cancer care, and the desire by the physicians for an all inclusive prostate treatment program, while allowing urologists to be more involved in the design, selection of treatment technology, and overall quality of care for their prostate cancer patients by working closely with the radiation oncologists in designing a cancer center with the intent of establishing a 'centers of excellence' for the treatment and ultimate cure of prostate related disease.

Oncology Med's turnkey cancer center model is fully compliant with all federal and state statutes and regulations. These are inclusive of all Stark and anti-kickback legislation. In addition, each geographical region is researched in depth by legal counsel prior to any business activity or formation to provide an independent opinion as to the model and any changes in regulatory rules and regulations which might affect the model.

"We have worked for over a year to develop our turnkey prostate cancer center model," stated William 'Bill' Walker, PhD, CEO of Oncology Med (OMI). "The model is designed to establish 'centers of excellence' and to be a win-win for the patients, physicians, and payers while providing a total continuity of care for each patient." "In the past many surgeons were really taken out of the process once a patient was referred to radiation oncologists for treatment of their prostate cancer; however, under Oncology Med's program, the urologists are involved with the decision making surrounding their patient's treatment program including the selection of cutting edge technology for a curative approach to the treatment of prostate cancer and other cancers of the urinary tract," he continued.

According to Jack Sloan, Senior Vice President of Business Development for OMI, "Radiation therapy treatment in any combination of low dose radiation (LDR - seeds), high dose radiation (HDR), intensity modulated radiation therapy (IMRT), and/or external beam radiation therapy (EBRT) continues to be the treatment of choice in site specific cancers contained within selective organs or limited to selective sites of the body," "According to the American Cancer Society, 58% of estimated newly diagnosed cancer cases in 2007 were found in the urinary, genital, respiratory, and digestive systems with the largest number of site specific cancers being diagnosed in the prostate and breast accounting for over 399,000 new cases in 2007 or 28% of the total number of new cancer cases diagnosed that year," Sloan continued.

"Some of the basic components that we will supply for these turnkey centers will be medical physics, acceptance and commissioning of equipment, staffing, business and/or clinical management, architectural development, general contracting, business modeling, billing/collection services, marketing/sales, and potentially a small percentage investment ownership by OMI in each of the centers," Sloan enthusiastically added.

"We anticipate the cancer centers we help develop and establish to be part of a national cancer treatment network that will benchmark on best practices and treatments, as well as, developed better efficiencies and business practices to be truly 'centers of excellence' in the treatment of cancer, " added Walker. "Our initial presentations to several select physician groups have been extremely positive and we anticipate our first cancer center development contracts to be forthcoming in the near future," Walker concluded.

In addition to its turnkey prostate cancer center model, Oncology Med continues to provide a full range of services for all existing cancer centers and those new cancer centers under consideration and/or development. OMI also continues to provide full turnkey programs for ambulatory surgery centers (ASC's) and hospitals for low dose radiation (LDR) brachytherapy (seeds) treatment of prostate cancer and was the first agency to license an ASC to perform such services when CMS first approved the procedure to be reimbursed in an ASC in 2003. Since that time, Oncology Med has been instrumental in licensing and bringing up new prostate cancer brachytherapy programs at ASCs in over 12 states and is considered the leading authority on ASC licensing and implementation of prostate cancer brachytherapy programs.

Oncology Med continues to expand and provide extensive consultation services for new and expanded cancer center construction, certification and credentialing processes for Joint Commission, as well as, physics staffing and support, and complete turnkey solutions for continuation or implementation of radiation treatment programs for ambulatory surgery centers, radiation oncologists, urologists, and hospitals.

About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation treatments to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
More information about Oncology Med, Inc. can be found at http://www.oncologymed.com.

Note: This press release may contain ``forward-looking statements.'' In some cases, you can identify forward-looking statements by terminology such as ``may,'' ``will,'' ``should,'' ``could,'' ``expects,'' ``plans,'' ``intends,'' ``anticipates,'' ``believes,'' ``estimates,'' ``predicts,'' ``potential,'' ``continue'' or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results.

For information, please contact:
William Walker, Ph.D.
President/CEO
(540) 822-5161
wwalker@oncologymed.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

WILLIAM WALKER

JACK SLOAN

(615) 591-2822
Email >
Visit website